Antibiotic susceptibility and resistance gene analysis of Haemophilus influenza in clinical tebipenem-pivoxil studies in pediatric patients using PCR method

Kozue Kishii, Naoko Chiba, Miyuki Morozumi, Keiko Hamano-Hasegawa, Kimiko Ubukata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We isolated 158 Haemophilus influenzae strains from pediatric patients enrolled in Phase II and III clinical studies of tebipenem pivoxil(TBPM-PI), and identified them as causative pathogens. These consisted of 112 isolates from patients with acute otitis media(AOM), 16 from those with acute sinusitis, and 30 from those with pneumonia. Mutation(s) of the ftsI gene encoding PBP3 involved in β-lactam resistance were identified in all isolates and classified into six groups based on genetic mutation. gBLNAR strains predominated at 51.9%, followed by gLow-BLNAR at 8.2%, gBLPACR-II at 1.9%, and gBLPACR-I at 0.6%. gBLNAS accounted for only 36.7%. The TBPM MIC90 against gBLNAR was 1.0 μg/mL, an excellent result, following that of cefditoren at 0.25 μg/mL. MIC90 of other oral antibiotics against gBLNAR were 8 μg/mL for ampicillin and faropenem and 32 μg/mL for amoxicillin and cefdinir. Of H. influenzae strains, 94.9% were nontypable, without a polysaccharide capsule. Sequencing of the ftsI gene suggested that further substitution of amino acids at other sites had gradually begun. A comparison of the DNA restriction pattern by PFGE after digestion with SmaI for randomized gBLNAR showed significant diversity. These results suggest that TBPM is bacteriologically efficacious against AOM and other pediatric respiratory infections caused by gBLNAR.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalJapanese Journal of Chemotherapy
Volume57
Issue numberSUPPL. 1
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

cefdinir
Haemophilus influenzae
Otitis Media
Microbial Drug Resistance
Pediatrics
Lactams
Polymerase Chain Reaction
Mutation
Sinusitis
Amoxicillin
Amino Acid Substitution
Ampicillin
Respiratory Tract Infections
Genes
Capsules
Polysaccharides
Digestion
Pneumonia
Anti-Bacterial Agents
DNA

Keywords

  • Child
  • Drug susceptibility
  • Haemophilus influenzae
  • PBP-3
  • Tebipenem

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antibiotic susceptibility and resistance gene analysis of Haemophilus influenza in clinical tebipenem-pivoxil studies in pediatric patients using PCR method. / Kishii, Kozue; Chiba, Naoko; Morozumi, Miyuki; Hamano-Hasegawa, Keiko; Ubukata, Kimiko.

In: Japanese Journal of Chemotherapy, Vol. 57, No. SUPPL. 1, 03.2009, p. 67-75.

Research output: Contribution to journalArticle

Kishii, Kozue ; Chiba, Naoko ; Morozumi, Miyuki ; Hamano-Hasegawa, Keiko ; Ubukata, Kimiko. / Antibiotic susceptibility and resistance gene analysis of Haemophilus influenza in clinical tebipenem-pivoxil studies in pediatric patients using PCR method. In: Japanese Journal of Chemotherapy. 2009 ; Vol. 57, No. SUPPL. 1. pp. 67-75.
@article{206f980142804e70ba3f1be7ed25d70c,
title = "Antibiotic susceptibility and resistance gene analysis of Haemophilus influenza in clinical tebipenem-pivoxil studies in pediatric patients using PCR method",
abstract = "We isolated 158 Haemophilus influenzae strains from pediatric patients enrolled in Phase II and III clinical studies of tebipenem pivoxil(TBPM-PI), and identified them as causative pathogens. These consisted of 112 isolates from patients with acute otitis media(AOM), 16 from those with acute sinusitis, and 30 from those with pneumonia. Mutation(s) of the ftsI gene encoding PBP3 involved in β-lactam resistance were identified in all isolates and classified into six groups based on genetic mutation. gBLNAR strains predominated at 51.9{\%}, followed by gLow-BLNAR at 8.2{\%}, gBLPACR-II at 1.9{\%}, and gBLPACR-I at 0.6{\%}. gBLNAS accounted for only 36.7{\%}. The TBPM MIC90 against gBLNAR was 1.0 μg/mL, an excellent result, following that of cefditoren at 0.25 μg/mL. MIC90 of other oral antibiotics against gBLNAR were 8 μg/mL for ampicillin and faropenem and 32 μg/mL for amoxicillin and cefdinir. Of H. influenzae strains, 94.9{\%} were nontypable, without a polysaccharide capsule. Sequencing of the ftsI gene suggested that further substitution of amino acids at other sites had gradually begun. A comparison of the DNA restriction pattern by PFGE after digestion with SmaI for randomized gBLNAR showed significant diversity. These results suggest that TBPM is bacteriologically efficacious against AOM and other pediatric respiratory infections caused by gBLNAR.",
keywords = "Child, Drug susceptibility, Haemophilus influenzae, PBP-3, Tebipenem",
author = "Kozue Kishii and Naoko Chiba and Miyuki Morozumi and Keiko Hamano-Hasegawa and Kimiko Ubukata",
year = "2009",
month = "3",
language = "English",
volume = "57",
pages = "67--75",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Antibiotic susceptibility and resistance gene analysis of Haemophilus influenza in clinical tebipenem-pivoxil studies in pediatric patients using PCR method

AU - Kishii, Kozue

AU - Chiba, Naoko

AU - Morozumi, Miyuki

AU - Hamano-Hasegawa, Keiko

AU - Ubukata, Kimiko

PY - 2009/3

Y1 - 2009/3

N2 - We isolated 158 Haemophilus influenzae strains from pediatric patients enrolled in Phase II and III clinical studies of tebipenem pivoxil(TBPM-PI), and identified them as causative pathogens. These consisted of 112 isolates from patients with acute otitis media(AOM), 16 from those with acute sinusitis, and 30 from those with pneumonia. Mutation(s) of the ftsI gene encoding PBP3 involved in β-lactam resistance were identified in all isolates and classified into six groups based on genetic mutation. gBLNAR strains predominated at 51.9%, followed by gLow-BLNAR at 8.2%, gBLPACR-II at 1.9%, and gBLPACR-I at 0.6%. gBLNAS accounted for only 36.7%. The TBPM MIC90 against gBLNAR was 1.0 μg/mL, an excellent result, following that of cefditoren at 0.25 μg/mL. MIC90 of other oral antibiotics against gBLNAR were 8 μg/mL for ampicillin and faropenem and 32 μg/mL for amoxicillin and cefdinir. Of H. influenzae strains, 94.9% were nontypable, without a polysaccharide capsule. Sequencing of the ftsI gene suggested that further substitution of amino acids at other sites had gradually begun. A comparison of the DNA restriction pattern by PFGE after digestion with SmaI for randomized gBLNAR showed significant diversity. These results suggest that TBPM is bacteriologically efficacious against AOM and other pediatric respiratory infections caused by gBLNAR.

AB - We isolated 158 Haemophilus influenzae strains from pediatric patients enrolled in Phase II and III clinical studies of tebipenem pivoxil(TBPM-PI), and identified them as causative pathogens. These consisted of 112 isolates from patients with acute otitis media(AOM), 16 from those with acute sinusitis, and 30 from those with pneumonia. Mutation(s) of the ftsI gene encoding PBP3 involved in β-lactam resistance were identified in all isolates and classified into six groups based on genetic mutation. gBLNAR strains predominated at 51.9%, followed by gLow-BLNAR at 8.2%, gBLPACR-II at 1.9%, and gBLPACR-I at 0.6%. gBLNAS accounted for only 36.7%. The TBPM MIC90 against gBLNAR was 1.0 μg/mL, an excellent result, following that of cefditoren at 0.25 μg/mL. MIC90 of other oral antibiotics against gBLNAR were 8 μg/mL for ampicillin and faropenem and 32 μg/mL for amoxicillin and cefdinir. Of H. influenzae strains, 94.9% were nontypable, without a polysaccharide capsule. Sequencing of the ftsI gene suggested that further substitution of amino acids at other sites had gradually begun. A comparison of the DNA restriction pattern by PFGE after digestion with SmaI for randomized gBLNAR showed significant diversity. These results suggest that TBPM is bacteriologically efficacious against AOM and other pediatric respiratory infections caused by gBLNAR.

KW - Child

KW - Drug susceptibility

KW - Haemophilus influenzae

KW - PBP-3

KW - Tebipenem

UR - http://www.scopus.com/inward/record.url?scp=65249110379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249110379&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:65249110379

VL - 57

SP - 67

EP - 75

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -